Join us at the 3rd annual Gene Therapy and Analytical Development virtual conference. The annual gathering attracts over 500 attendees, including CMC, Regulatory, QC, and analytical and process development experts as they discuss analytical development challenges in relation to gene therapy drug development. The conference will feature three tracks of learning, Bioassays, Molecular Biology, and Analytical Chemistry, each including case studies, panel discussions, and Q+A sessions.
Jeffrey Hung, PhD
a Charles River Company
Wednesday, December 1st - Analytical Chemistry Track
AAV Empty: Full Capsid Ratio - A Comparative Study for the CQA Using TEM, AUC, DLS, and qPCR/ELISA
Dr. Hung has over 20 years of experience in gene therapy, synthetic biology, and drug development. He joined Vigene in 2016 and orchestrated the acquisition of Omnia Biologics, a GMP manufacturer of viral vectors of 15 years. He has also overseen Vigene's expansion into GMP manufacturing and new product areas such as biosensors. An experienced entrepreneur, Dr. Hung was instrumental in successfully growing GenScript and SABiosciences, two previous companies, to IPO and acquisition stage, respectively. He also previously held the position of Chief Marketing Officer at ATCC. Jeffrey is the author of multiple patents, publications, and book chapters. He holds a Ph.D. in Genetics from Cornell University, an MBA from UC Berkeley, and a B.S. in Biology from Peking University.